IL187508A0 - Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment - Google Patents

Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Info

Publication number
IL187508A0
IL187508A0 IL187508A IL18750807A IL187508A0 IL 187508 A0 IL187508 A0 IL 187508A0 IL 187508 A IL187508 A IL 187508A IL 18750807 A IL18750807 A IL 18750807A IL 187508 A0 IL187508 A0 IL 187508A0
Authority
IL
Israel
Prior art keywords
rapamycins
combination therapy
cancer treatment
urea compound
mtor inhibitors
Prior art date
Application number
IL187508A
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of IL187508A0 publication Critical patent/IL187508A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL187508A 2005-05-27 2007-11-20 Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment IL187508A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011477 2005-05-27
PCT/EP2006/004524 WO2006125540A1 (en) 2005-05-27 2006-05-13 Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Publications (1)

Publication Number Publication Date
IL187508A0 true IL187508A0 (en) 2008-06-05

Family

ID=36636325

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187508A IL187508A0 (en) 2005-05-27 2007-11-20 Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment

Country Status (11)

Country Link
EP (1) EP1888067A1 (en)
JP (1) JP2008542214A (en)
KR (1) KR20080018908A (en)
CN (1) CN101257903A (en)
AU (1) AU2006251429A1 (en)
BR (1) BRPI0610048A2 (en)
CA (1) CA2609389A1 (en)
IL (1) IL187508A0 (en)
MX (1) MX2007014726A (en)
RU (1) RU2007148266A (en)
WO (1) WO2006125540A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
UY28213A1 (en) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diaryl ureas for diseases mediated by pdgfr
ES2297490T3 (en) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation OMEGA-CARBOXIARILDIFENILUREA FLUORO REPLACED FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS.
JP5304241B2 (en) 2005-03-07 2013-10-02 バイエル・ヘルスケア・エルエルシー Pharmaceutical composition comprising omega-carboxyaryl substituted diphenylurea for the treatment of cancer
US20100129321A1 (en) * 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
AR062927A1 (en) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE
US20100173954A1 (en) * 2007-01-19 2010-07-08 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP2011525503A (en) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Diarylureas for treating heart failure
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
CA2763589A1 (en) * 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CN102775385A (en) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-substituted phenyl-N'-substituted heterocyclic urea compounds and application of same as anti-cancer drugs
CN102643229A (en) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-chloro-3-trifluoromethyl) phenyl)-N'-((2-fluoro-4-(2-formamyl)-4-pyridyloxy) phenyl) urea and application thereof serving as anticancer medicament
CN102885814A (en) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 Compound and use of compound as anti-cancer medicine
CN102940884B (en) * 2012-11-19 2013-11-06 上海市肿瘤研究所 Inhibitor for hepatoma carcinoma cell and application in aspect of inhibiting tumor growth thereof
US10420761B2 (en) 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
KR102016822B1 (en) * 2014-12-17 2019-08-30 화이자 인코포레이티드 Formulations of a pi3k/mtor-inhibitor for intravenous administration
CN104892632B (en) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 A kind of everolimus of crystal form and preparation method thereof
CN104906086A (en) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 Application of indole-3-methaol, bis(indoly)methane and derivatives thereof in medicine for treating glomerulonephritis
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
KR102544163B1 (en) * 2022-08-10 2023-06-16 주식회사 하이밸 Noise reduction type pressure reducing valve for flow and pressure control
CN115804844B (en) * 2022-09-26 2024-05-10 郑州大学 Application of inhibitor for targeted inhibition of PAK4 in preparation of tumor prevention and treatment medicament

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297490T3 (en) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation OMEGA-CARBOXIARILDIFENILUREA FLUORO REPLACED FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS.

Also Published As

Publication number Publication date
EP1888067A1 (en) 2008-02-20
RU2007148266A (en) 2009-07-10
WO2006125540A1 (en) 2006-11-30
MX2007014726A (en) 2008-02-14
CA2609389A1 (en) 2006-11-30
CN101257903A (en) 2008-09-03
AU2006251429A1 (en) 2006-11-30
KR20080018908A (en) 2008-02-28
BRPI0610048A2 (en) 2010-05-25
JP2008542214A (en) 2008-11-27

Similar Documents

Publication Publication Date Title
IL187508A0 (en) Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
IL187085A0 (en) Combination therapy comprising diaryl ureas for treating diseases
EP1487436A4 (en) Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP2024018A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
IL188588A0 (en) Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
ZA200904518B (en) Zone coated filter, emission treatment systems and methods
HK1098072A1 (en) Medicaments and methods for treating headache
IL191938A (en) Bicyclic heteroaryl compounds, pharmaceutical compositions comprising them and bicyclic heteroaryl compounds for use in treating cancer
HK1250018B (en) Rapamycin derivative for treating pancreas cancer
IL187327A0 (en) Methods for treating drug resistant cancer
HK1103354A1 (en) Combination therapy for preventing or treating alzheimers disease, and kit therefor
EP1535971A4 (en) Treated pigment, use thereof, and compound for pigment treatment
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
IL180256A0 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
EP1680073A4 (en) Compounds and method for treating cancer
MX2008015775A (en) Compounds and compositions for treatment of cancer.
BRPI0618198A2 (en) cancer and lymphoma treatment, prevention or inhibition methods, composition, kit, and therapy resistant cancer treatment method
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
EP2574340A3 (en) Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
EP1836165A4 (en) Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
IL226362A0 (en) Compounds, and methods for the treatment of cancer
AU2003281908A1 (en) Collimator, x-ray irradiator, and x-ray apparatus
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2007010012A3 (en) Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor